Provided by Tiger Fintech (Singapore) Pte. Ltd.

AIM ImmunoTech

0.1260
-0.0070-5.26%
Post-market: 0.13000.0040+3.17%17:36 EDT
Volume:471.58K
Turnover:62.61K
Market Cap:8.66M
PE:-0.28
High:0.1420
Open:0.1410
Low:0.1260
Close:0.1330
Loading ...

AIM ImmunoTech Doses First Subject in Phase 2 of Late-Stage Pancreatic Cancer Study

MT Newswires Live
·
26 Feb

Aim Doses First New Subject in Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer

THOMSON REUTERS
·
25 Feb

AIM Doses First New Subject in Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer

GlobeNewswire
·
25 Feb

AIM Vaccine Submits US Clinical Trial Application for Shingles Jab

MT Newswires Live
·
24 Feb

ALT Resources to Acquire Mining Royalty and Move to AIM

TIPRANKS
·
24 Feb

AIM Vaccine’s mRNA Shingles Vaccine Advances with Promising Preclinical Results

TIPRANKS
·
23 Feb

AIM Vaccine Co., Ltd. Integrates AI for Strategic Upgrade

TIPRANKS
·
23 Feb

Unicorn AIM VCT Expands Share Capital Through Dividend Reinvestment

TIPRANKS
·
21 Feb

Wellnex directors commit to $1.5 million in entitlement offer ahead of London listing

Stockheads
·
21 Feb

London calling: Wellnex Life secures $14.3 million for LSE listing

Stockheads
·
20 Feb

Wellnex Life Secures Funding for Dual Listing on AIM

TIPRANKS
·
20 Feb

Wellnex Life secures $14.3m for dual listing on London Stock Exchange

Small Caps
·
20 Feb

Market Sentiment Around Loss-Making Ai-Media Technologies Limited (ASX:AIM)

Simply Wall St.
·
20 Feb

Octopus AIM VCT Director Takes on New Role at Cake Box Holdings

TIPRANKS
·
20 Feb

Argo Group Limited Concludes Tender Offer and Announces AIM Delisting

TIPRANKS
·
19 Feb

Hargreave Hale AIM VCT 1 Faces Challenging Start Amid Economic Uncertainty

TIPRANKS
·
17 Feb